AbbVie Current Ratio 2010-2024 | ABBV

Current and historical current ratio for AbbVie (ABBV) from 2010 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. AbbVie current ratio for the three months ending March 31, 2024 was 0.94.
AbbVie Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2024-03-31 $38.87B $41.52B 0.94
2023-12-31 $33.00B $37.84B 0.87
2023-09-30 $33.22B $34.77B 0.96
2023-06-30 $28.85B $32.24B 0.90
2023-03-31 $26.49B $27.59B 0.96
2022-12-31 $28.46B $29.54B 0.96
2022-09-30 $30.36B $32.71B 0.93
2022-06-30 $29.10B $34.47B 0.84
2022-03-31 $26.51B $32.52B 0.82
2021-12-31 $27.93B $35.19B 0.79
2021-09-30 $28.96B $28.53B 1.02
2021-06-30 $26.00B $28.68B 0.91
2021-03-31 $26.57B $31.95B 0.83
2020-12-31 $24.17B $28.66B 0.84
2020-09-30 $23.01B $24.18B 0.95
2020-06-30 $21.26B $24.65B 0.86
2020-03-31 $51.76B $16.47B 3.14
2019-12-31 $49.52B $15.59B 3.18
2019-09-30 $20.17B $17.49B 1.15
2019-06-30 $15.10B $16.94B 0.89
2019-03-31 $14.41B $13.90B 1.04
2018-12-31 $16.95B $17.24B 0.98
2018-09-30 $18.47B $15.39B 1.20
2018-06-30 $13.85B $17.22B 0.80
2018-03-31 $20.44B $17.06B 1.20
2017-12-31 $21.22B $16.64B 1.28
2017-09-30 $18.93B $13.03B 1.45
2017-06-30 $16.96B $12.26B 1.38
2017-03-31 $15.55B $8.84B 1.76
2016-12-31 $16.19B $9.78B 1.66
2016-09-30 $16.29B $9.10B 1.79
2016-06-30 $16.79B $9.27B 1.81
2016-03-31 $16.62B $10.66B 1.56
2015-12-31 $16.31B $10.89B 1.50
2015-09-30 $17.91B $8.81B 2.03
2015-06-30 $16.88B $11.26B 1.50
2015-03-31 $15.41B $11.05B 1.39
2014-12-31 $16.08B $11.39B 1.41
2014-09-30 $17.56B $6.64B 2.65
2014-06-30 $17.79B $6.32B 2.82
2014-03-31 $17.33B $6.22B 2.79
2013-12-31 $17.85B $6.88B 2.60
2013-09-30 $16.54B $6.88B 2.41
2013-06-30 $15.66B $6.81B 2.30
2013-03-31 $14.92B $6.77B 2.21
2012-12-31 $15.35B $6.78B 2.27
2012-09-30 $10.93B $5.37B 2.04
2012-06-30 $5.99B $4.84B 1.24
2012-03-31 $6.75B $5.52B 1.22
2011-12-31 $7.35B $5.90B 1.25
2011-09-30 $0.00B 0.00
2011-06-30 $0.00B 0.00
2011-03-31 $0.00B 0.00
2010-12-31 $8.22B $3.76B 2.19
2009-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $304.294B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $814.944B 117.78
Novo Nordisk (NVO) Denmark $590.290B 45.36
Johnson & Johnson (JNJ) United States $372.289B 14.76
Merck (MRK) United States $318.551B 57.96
AstraZeneca (AZN) United Kingdom $244.043B 21.22
Novartis AG (NVS) Switzerland $216.930B 15.08
Pfizer (PFE) United States $169.828B 21.11
Sanofi (SNY) $128.207B 12.08
Innoviva (INVA) United States $1.073B 7.54